Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 59.7% | 194.8% | 70.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36.2% | 42.6% | 54.1% | 10% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 1% | -0.1% | -58% | -235.3% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -236% | -243.7% | 110.2% | 737% |
| EPS Diluted | -0.016 | -0.011 | 0.002 | 0.012 |
| % Growth | -41.2% | -733.3% | -85.1% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |